117 related articles for article (PubMed ID: 30113582)
1. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
[TBL] [Abstract][Full Text] [Related]
2. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
4. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K; Ross CJ; Visscher H; Yazdanpanah M; Brooks B; Rassekh SR; Zada YF; Dubé MP; Carleton BC; Hayden MR;
Clin Pharmacol Ther; 2013 Aug; 94(2):243-51. PubMed ID: 23588304
[TBL] [Abstract][Full Text] [Related]
5. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Hagleitner MM; Coenen MJ; Patino-Garcia A; de Bont ES; Gonzalez-Neira A; Vos HI; van Leeuwen FN; Gelderblom H; Hoogerbrugge PM; Guchelaar HJ; Te Loo MW
PLoS One; 2014; 9(12):e115869. PubMed ID: 25551397
[TBL] [Abstract][Full Text] [Related]
6. Challenges in interpreting the evidence for genetic predictors of ototoxicity.
Ratain MJ; Cox NJ; Henderson TO
Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639
[TBL] [Abstract][Full Text] [Related]
7. Genetics of cisplatin ototoxicity: confirming the unexplained?
Boddy AV
Clin Pharmacol Ther; 2013 Aug; 94(2):198-200. PubMed ID: 23872836
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience.
Soliman SE; D'Silva CN; Dimaras H; Dzneladze I; Chan H; Gallie BL
Pediatr Blood Cancer; 2018 May; 65(5):e26931. PubMed ID: 29350448
[TBL] [Abstract][Full Text] [Related]
9. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
10. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Yang JJ; Lim JY; Huang J; Bass J; Wu J; Wang C; Fang J; Stewart E; Harstead EH; E S; Robinson GW; Evans WE; Pappo A; Zuo J; Relling MV; Onar-Thomas A; Gajjar A; Stewart CF
Clin Pharmacol Ther; 2013 Aug; 94(2):252-9. PubMed ID: 23820299
[TBL] [Abstract][Full Text] [Related]
11. Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC; Ross CJ; Pussegoda K; Bhavsar AP; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
Clin Pharmacol Ther; 2014 Sep; 96(3):296-8. PubMed ID: 25141953
[TBL] [Abstract][Full Text] [Related]
12. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC; Ross CJ; Bhavsar AP; Amstutz U; Pussegoda K; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
Clin Pharmacol Ther; 2014 Mar; 95(3):253. PubMed ID: 24193170
[No Abstract] [Full Text] [Related]
13. Pharmacogenomics of cisplatin-induced ototoxicity.
Mukherjea D; Rybak LP
Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.
Lanvers-Kaminsky C; Malath I; Deuster D; Ciarimboli G; Boos J; Am Zehnhoff-Dinnesen AG
Clin Pharmacol Ther; 2014 Aug; 96(2):156-7. PubMed ID: 24642735
[No Abstract] [Full Text] [Related]
15. Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC; Ross CJ; Bhavsar AP; Lee JW; Visscher H; Rassekh SR; Hayden MR
Clin Pharmacol Ther; 2014 Aug; 96(2):158. PubMed ID: 24755913
[No Abstract] [Full Text] [Related]
16. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
17. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
[TBL] [Abstract][Full Text] [Related]
18. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
[TBL] [Abstract][Full Text] [Related]
19. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
20. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
